# US 2013/0253064 A1 · Styrenyl derivative compounds for treating ophthalmic diseases and disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0253064 A1
- Document ID: US20130253064A1
- Status: Published application
- Kind: A1
- Application number: 13/789,259
- Filed: 2013-03-07
- Published: 2013-09-26
- Earliest claimed: 2007-04-20
- Assignees: Acucela Inc.
- Inventors: Ian Leslie Scott; Vladimir Aleksandrovich Kuksa; Anna Gall; Mark W. Orme; Jennifer Gage; Thomas L. Little, JR.; Qin Jiang; Lana Michele Rossiter; Kevin F. McGee, JR.; Ryo Kubota
- Web page: https://patentgrep.com/patent/US20130253064A1

## CPC

- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/145: having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2) (isothiourea A61K31/155)
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/4453: only substituted in position 1, e.g. propipocaine, diperodon
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/10: for accommodation disorders, e.g. myopia
- A61P 35/00: Antineoplastic agents
- C07C 211/27: having amino groups linked to the six-membered aromatic ring by saturated carbon chains
- C07C 211/28: having amino groups linked to the six-membered aromatic ring by unsaturated carbon chains
- C07C 211/29: the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
- C07C 215/08: with only one hydroxy group and one amino group bound to the carbon skeleton
- C07C 215/30: containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
- C07C 215/42: having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C 215/46: having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C 217/10: to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
- C07C 217/16: the six-membered aromatic ring or condensed ring system containing that ring not being further substituted
- C07C 217/18: the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C 217/48: the carbon skeleton being unsaturated and containing rings
- C07C 217/54: having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C 217/62: linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
- C07C 217/72: linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
- C07C 225/06: and acyclic
- C07C 225/18: the carbon skeleton containing also rings other than six-membered aromatic rings
- C07C 233/05: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 237/04: the carbon skeleton being acyclic and saturated
- C07C 317/28: with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C 323/25: the carbon skeleton being acyclic and saturated
- C07C 323/32: having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
- C07C 323/33: having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring
- C07D 207/06: with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D 211/14: with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C07D 295/03: with the ring nitrogen atoms directly attached to acyclic carbon atoms
- C07C 2602/14: All rings being cycloaliphatic
- C07C 2602/16: the ring system containing five carbon atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

## Claims

### Claim at position 1

-84. (canceled)

### Claim 85

A method for treating an ophthalmic disease or disorder resulting at least in part from lipofuscin pigment accumulation in an eye of a subject, comprising administering to the subject a pharmaceutical composition comprising a compound having a structure of Formula (E):
as an isolated E or Z geometric isomer or a mixture of E and Z geometric isomers, as a tautomer or a mixture of tautomers, as a stereoisomer, or as a pharmaceutically acceptable salt, hydrate, solvate, or N-oxide thereof, wherein:
R1 and R2 are each the same or different and independently hydrogen;
R3, R4, R5 and R6 are each the same or different and independently hydrogen, halogen, —OR12, alkyl or fluoroalkyl;
R7 and R8 are each the same or different and independently hydrogen;
each R12 is independently selected from hydrogen or alkyl;
R14 and R15 are each the same or different and independently hydrogen, halogen, alkyl, fluoroalkyl, —OR12, or —NR18R19; or R14 and R15 form an oxo;
R16 and R17 are each the same or different and independently hydrogen, halogen, alkyl, fluoroalkyl, —OR12, or —NR18R19; or R16 and R17 form an oxo;
each R18 and R19 are each the same or different and independently hydrogen or alkyl;
t is 0, 1, 2, or 3; and
each R20 is the same or different and independently alkyl, —OR12, —SR12, alkenyl, alkynyl, halogen, fluoroalkyl, aryl or aralkyl, or two adjacent R20, together with the two carbon atoms to which they are attached, form a fused phenyl ring.

### Claim 86 (depends on 85)

The method of claim 85, wherein R14 and R15 are each independently hydrogen, halogen, alkyl or —OR12; and R16 and R17 are each independently hydrogen, halogen, alkyl or —OR12, wherein each R12 is independently selected from hydrogen or alkyl.

### Claim 87 (depends on 85)

The method of claim 85, wherein:
t is 2 or 3;
two adjacent R20, together with the two carbon atoms to which they are attached, form a fused phenyl ring; and
R3, R4, R5 and R6 are each independently hydrogen, alkyl, halogen or fluoroalkyl.

### Claim 88 (depends on 87)

The method of claim 87, wherein R14 and R15 are each independently hydrogen, halogen, alkyl or —OR12; and R16 and R17 are each independently hydrogen, halogen, alkyl or —OR12.

### Claim 89

A method for treating an ophthalmic disease or disorder resulting at least in part from lipofuscin pigment accumulation in an eye of a subject, comprising administering to the subject a pharmaceutical composition comprising a compound having a structure of Formula (G):
as an isolated E or Z geometric isomer or a mixture of E and Z geometric isomers, as a tautomer or a mixture of tautomers, as a stereoisomer, or as a pharmaceutically acceptable salt, hydrate, solvate, or N-oxide thereof, wherein:
R1 and R2 are hydrogen;
R3, R4, R5 and R6 are each the same or different and independently hydrogen, halogen, —OR12, alkyl or fluoroalkyl;
R7 and R8 are each the same or different and independently hydrogen or alkyl;
R9 is hydrogen or —C(═O)R13;
R10 is hydrogen;
each R12 is independently selected from hydrogen or alkyl;
R13 is alkyl;
R14 and R15 are each the same or different and independently hydrogen, halogen, alkyl, fluoroalkyl, —OR12, or —NR18R19; or R14 and R15 together form an oxo;
R16 and R17 are each the same or different and independently hydrogen, halogen, alkyl, fluoroalkyl, or —OR12; or R16 and R17 together form an oxo;
each R18 and R19 is independently selected from hydrogen or alkyl;
p is 0, 1, 2, 3, 4, or 5; and
each R21 is the same or different and independently alkyl, —OR12, halogen, or fluoroalkyl.

### Claim 90 (depends on 89)

The method of claim 89 wherein each of R9 and R10 is hydrogen.

### Claim 91 (depends on 90)

The method of claim 90 wherein:
p is 0, 1, 2 or 3; and
each R21 is independently alkyl, halogen or fluoroalkyl.

### Claim 92 (depends on 91)

The method of claim 91, wherein R14 and R15 are each independently hydrogen, halogen, alkyl, fluoroalkyl, —OR12 or —NR18R19; and R16 and R17 are each independently hydrogen, halogen, alkyl, fluoroalkyl, or —OR12, wherein each R12 is independently hydrogen or alkyl; and
each R18 and R19 are independently hydrogen or alkyl.

### Claim 93 (depends on 89)

The method of claim 89 wherein R9 is alkyl and R10 is hydrogen.

### Claim 94 (depends on 93)

The method of claim 93, wherein R14 and R15 are each independently hydrogen, halogen, alkyl, fluoroalkyl or —OR12; and R16 and R17 are each independently hydrogen, halogen, alkyl, fluoroalkyl or —OR12, wherein each R12 is independently hydrogen or alkyl.

### Claim 95 (depends on 89)

The method of claim 89 wherein R16 and R17 are each independently hydrogen, halogen, alkyl, fluoroalkyl or —OR12, wherein R12 is hydrogen or alkyl; and R14 and R15 together form oxo.

### Claim 96

A method for treating an ophthalmic disease or disorder resulting at least in part from lipofuscin pigment accumulation in an eye of a subject, comprising administering to the subject a pharmaceutical composition comprising a compound having a structure of Formula (A):
as an isolated E or Z geometric isomer or a mixture of E and Z geometric isomers, as a tautomer or a mixture of tautomers, as a stereoisomer or as a pharmaceutically acceptable salt, hydrate, solvate, or N-oxide thereof, wherein:
R1 and R2 are each the same or different and independently hydrogen or alkyl;
R3, R4, R5 and R6 are each the same or different and independently hydrogen, halogen, —OR12, alkyl or fluoroalkyl;
R7 and R8 are hydrogen;
R9 and R10 are hydrogen;
R11 is alkyl;
each R12 is independently selected from hydrogen or alkyl;
Z is W—Y, wherein
W is —C(R14)(R15)—;
Y is —C(R16)(R17)—;
R14 and R15 are each the same or different and independently hydrogen, halogen, alkyl, fluoroalkyl, —OR12, or —NR18R19; or R14 and R15 together form an oxo;
R16 and R17 are each the same or different and independently hydrogen, halogen, alkyl, fluoroalkyl, —OR12, or —NR18R19; or R16 and R17 together form an oxo; or
optionally, R14 and R16 together form a direct bond to provide a double bond connecting W and Y; or optionally, R14 and R16 together form a direct bond, and R15 and R17 together form a direct bond to provide a triple bond connecting W and Y; and
each R18 and R19 is independently selected from hydrogen or alkyl.

### Claim 97

A method for treating an ophthalmic disease or disorder resulting at least in part from lipofuscin pigment accumulation in an eye of a subject, comprising administering to the subject a pharmaceutical composition comprising a compound selected from:
(E)-3-(3-(2,6-dimethylstyryl)phenyl)propan-1-amine;
(Z)-3-(3-(2,6-dimethylstyryl)phenyl)propan-1-amine;
(E)-3-(3-(2-methylstyryl)phenyl)propan-1-amine;
(Z)-3-(3-(2-methylstyryl)phenyl)propan-1-amine;
(E)-3-(3-(2,6-dimethylstyryl)-2-methylphenyl)propan-1-amine;
(Z)-3-(3-(2,6-dimethylstyryl)-2-methylphenyl)propan-1-amine;
(E/Z)-3-(3-(2-ethyl-6-methylstyryl)phenyl)propan-1-amine;
(E/Z)-3-(3-(2,5-dimethylstyryl)phenyl)propan-1-amine;
(E/Z)-3-(3-(2,4-dimethylstyryl)phenyl)propan-1-amine;
(E)-3-(3-(2,4,6-trimethylstyryl)phenyl)propan-1-amine;
(E/Z)-3-(3-(2-ethylstyryl)phenyl)propan-1-amine;
(E/Z)-3-(3-(2-ethynylstyryl)phenyl)propan-1-amine;
(E/Z)-3-(3-(3,4-dimethylstyryl)phenyl)propan-1-amine;
(E/Z)-3-(3-(2-isopropylstyryl)phenyl)propan-1-amine;
(E/Z)-4-(3-(3,5-dimethylstyryl)phenyl)propan-1-amine;
(E/Z)-4-(3-(2-methoxystyryl)phenyl)propan-1-amine;
(E)-3-(3-(2,6-dichlorostyryl)phenyl)propan-1-amine;
(E/Z)-3-(3-(2,3-dimethylstyryl)phenyl)propan-1-amine;
(E)-3-(3-(2,6-dimethylstyryl)-4-fluorophenyl)propan-1-amine;
(E/Z)-3-(3-(2-(trifluoromethyl)styryl)phenyl)propan-1-amine;
(E)-3-(3-(2,6-dimethoxystyryl)phenyl)propan-1-amine;
(E)-3-(3-(2,6-bis(trifluoromethyl)styryl)phenyl)propan-1-amine;
(E)-3-amino-1-(3-(2,6-dichlorostyryl)phenyl)propan-1-ol;
(E)-3-amino-1-(3-(2-chloro-6-methylstyryl)phenyl)propan-1-ol;
(E)-2-(3-(3-aminopropyl)styryl)phenol;
(E)-3-(5-(2,6-dichlorostyryl)-2-methoxyphenyl)propan-1-amine;
(R,E)-1-amino-3-(3-(2,6-dichlorostyryl)phenyl)propan-2-ol;
(S,E)-1-amino-3-(3-(2,6-dichlorostyryl)phenyl)propan-2-ol;
(E/Z)-(3-(3-(2,6-diethoxystyryl)phenyl)propan-1-amine;
(E)-3-(3-(2-ethoxystyryl)phenyl)propan-1-amine;
(E/Z)-3-(3-(2-isopropoxystyryl)phenyl)propan-1-amine;
(E)-3-amino-1-(3-(2,6-dichlorostyryl)phenyl)propan-1-one;
(E)-1-amino-3-(3-(2,6-dichlorostyryl)phenyl)propan-2-one;
(R,E)-3-amino-1-(3-(2,6-dichlorostyryl)phenyl)propan-1-ol;
(S,E)-3-amino-1-(3-(2,6-dichlorostyryl)phenyl)propan-1-ol;
(S,E)-3-(3-(2,6-dichlorostyryl)phenyl)-2-fluoropropan-1-amine;
(E)-3-(3-(2,6-dichlorostyryl)phenyl)-2,2-difluoropropan-1-amine;
(Z)-3-(3-(2-(2-methoxyethoxy)styryl)phenyl)-propan-1-amine;
(E)-3-(3-(3-methoxystyryl)phenyl)propan-1-amine;
(Z)-3-(3-(4-chlorostyryl)phenyl)propan-1-amine;
(E)-3-(3-(2-(biphenyl-2-yl)vinyl)phenyl)propan-1-amine;
(E)-3-(3-(3-chlorostyryl)phenyl)propan-1-amine;
(E)-3-(3-(2-butoxystyryl)phenyl)propan-1-amine;
(E)-3-(3-(4-methoxystyryl)phenyl)propan-1-amine;
(Z)-3-(3-(2-Propoxystyryl)phenyl)propan-1-amine;
(E)-3-(5-(2-Chloro-6-(methylthio)styryl)-2-methoxyphenyl)propan-1-amine;
(E)-3-(3-(2-(1-methoxynaphthalen-2-yl)vinyl)phenyl)propan-1-amine;
(Z)-3-(3-(2-(naphthalen-1-yl)vinyl)phenyl)propan-1-amine;
(Z)-3-(3-(2-(3-methoxynaphthalen-2-yl)vinyl)phenyl)propan-1-amine;
(E/Z)-3-(3-(2-(2-methoxynaphthalen-1-yl)vinyl)phenyl)propan-1-amine;
(E)-3-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)propan-1-amine;
(E)-3-amino-1-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)propan-1-ol;
(S,E)-3-amino-1-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)propan-1-ol;
(R,E)-3-Amino-1-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)propan-1-ol;
(E)-2-methyl-3-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)propan-1-amine;
(E)-3-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)butan-1-amine;
(E)-3-(2-methyl-5-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)propan-1-amine;
(E/Z)-4-amino-2-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)butan-2-ol;
(E)-3-fluoro-3-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)propan-1-amine;
(E)-4-amino-1,1,1-trifluoro-2-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)butan-2-ol;
(E)-3-amino-2,2-dimethyl-1-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)propan-1-ol;
(E)-3-amino-2-methyl-1-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)propan-1-ol;
(E)-1-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)propane-1,3-diamine;
(E)-4,4,4-trifluoro-3-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)butan-1-amine;
(E)-3-methoxy-3-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)propan-1-amine;
(E)-4-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)butan-2-amine;
(E)-1-amino-3-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)propan-2-ol;
(E)-2-(3-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)propylamino)ethanol;
(E)-3-methoxy-N-methyl-3-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)propan-1-amine;
(E)-3-amino-1-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)propan-1-one;
(E)-3-amino-2,2-dimethyl-1-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)propan-1-one;
(E)-3-amino-2-methyl-1-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)propan-1-one;
(E)-3-amino-2-fluoro-1-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)propan-1-one;
(E)-2-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenoxy)ethanamine;
(E)-2-amino-N-(3-(2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)acetamide;
(E)-3-(3-(pent-1-enyl)phenyl)propan-1-amine;
(E)-3-(3-(hept-1-enyl)phenyl)propan-1-amine;
(E)-3-(3-(non-4-en-5-yl)phenyl)propan-1-amine;
(E)-4-(3-(3-aminopropyl)phenyl)-2-methylbut-3-en-2-ol;
(E)-4-(3-(3-aminopropyl)styryl)heptan-4-ol;
(E)-1-(3-(3-aminopropyl)phenyl)hex-1-en-3-ol;
(E)-1-(3-(3-aminopropyl)phenyl)-3-ethylpent-1-en-3-ol;
(E)-3-(3-(3-aminopropyl)phenyl)prop-2-en-1-ol;
(E)-3-(3-(3-methoxyprop-1-enyl)phenyl)propan-1-amine;
(Z)-3-amino-1-(3-(2,6-dimethylstyryl)phenyl)propan-1-one oxime;
(Z)-3-amino-1-(3-((E)-2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)propan-1-one oxime;
(Z)-3-(3-(2,6-dimethylstyryl)phenyl)-3-hydrazonopropan-1-amine;
(Z)-3-hydrazono-3-(3-((E)-2-(2,6,6-trimethylcyclohex-1-enyl)vinyl)phenyl)propan-1-amine;
(E)-1-(3-(3-aminopropyl)phenyl)-3-methylhex-1-en-3-ol; and
(E)-1-(3-(3-aminopropyl)phenyl)-3-ethylhex-1-en-3-ol.

### Claim 98 (depends on 85)

The method of claim 85 wherein the ophthalmic disease or disorder is age-related macular degeneration or Stargardt's macular dystrophy.

### Claim 99 (depends on 85)

The method according to claim 85 resulting in a reduction of lipofuscin pigment accumulated in an eye of the subject.

### Claim 100 (depends on 99)

The method of claim 99 wherein the lipofuscin pigment is N-retinylidene-N-retinyl-ethanolamine (A2E).

### Claim 101 (depends on 89)

The method of claim 89 wherein the ophthalmic disease or disorder is age-related macular degeneration or Stargardt's macular dystrophy.

### Claim 102 (depends on 89)

The method of claim 89 resulting in a reduction of lipofuscin pigment accumulated in an eye of the subject.

### Claim 103 (depends on 102)

The method of claim 102 wherein the lipofuscin pigment is N-retinylidene-N-retinyl-ethanolamine (A2E).

### Claim 104 (depends on 96)

The method of claim 96 wherein the ophthalmic disease or disorder is age-related macular degeneration or Stargardt's macular dystrophy.

### Claim 105 (depends on 96)

The method of claim 96 resulting in a reduction of lipofuscin pigment accumulated in an eye of the subject.

### Claim 106 (depends on 105)

The method of claim 105 wherein the lipofuscin pigment is N-retinylidene-N-retinyl-ethanolamine (A2E).

### Claim 107 (depends on 97)

The method of claim 97 wherein the ophthalmic disease or disorder is age-related macular degeneration or Stargardt's macular dystrophy.

### Claim 108 (depends on 97)

The method of claim 97 resulting in a reduction of lipofuscin pigment accumulated in an eye of the subject.

### Claim 109 (depends on 108)

The method of claim 108 wherein the lipofuscin pigment is N-retinylidene-N-retinyl-ethanolamine (A2E).
